Annual D&A
$516.70 K
+$418.10 K+424.04%
December 1, 2023
Summary
- As of February 7, 2025, RNAZ annual depreciation & amortization is $516.70 thousand, with the most recent change of +$418.10 thousand (+424.04%) on December 1, 2023.
- During the last 3 years, RNAZ annual D&A has risen by +$516.70 thousand (+100.00%).
- RNAZ annual D&A is now at all-time high.
Performance
RNAZ Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$127.50 K
-$15.30 K-10.71%
September 1, 2024
Summary
- As of February 7, 2025, RNAZ quarterly depreciation & amortization is $127.50 thousand, with the most recent change of -$15.30 thousand (-10.71%) on September 1, 2024.
- Over the past year, RNAZ quarterly D&A has dropped by -$11.30 thousand (-8.14%).
- RNAZ quarterly D&A is now -10.71% below its all-time high of $142.80 thousand, reached on June 1, 2024.
Performance
RNAZ Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$552.10 K
-$11.30 K-2.01%
September 1, 2024
Summary
- As of February 7, 2025, RNAZ TTM depreciation & amortization is $552.10 thousand, with the most recent change of -$11.30 thousand (-2.01%) on September 1, 2024.
- Over the past year, RNAZ TTM D&A has increased by +$146.00 thousand (+35.95%).
- RNAZ TTM D&A is now -2.01% below its all-time high of $563.40 thousand, reached on June 1, 2024.
Performance
RNAZ TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
RNAZ Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +424.0% | -8.1% | +36.0% |
| 3 y3 years | +100.0% | +1600.0% | +3989.6% |
| 5 y5 years | - | +100.0% | +100.0% |
RNAZ Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1115.8% | -10.7% | +490.3% | -2.0% | +1199.1% |
| 5 y | 5-year | at high | -100.0% | -10.7% | -100.0% | -2.0% | -100.0% |
| alltime | all time | at high | -100.0% | -10.7% | -100.0% | -2.0% | -100.0% |
TransCode Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $127.50 K(-10.7%) | $552.10 K(-2.0%) |
| Jun 2024 | - | $142.80 K(+0.8%) | $563.40 K(+0.9%) |
| Mar 2024 | - | $141.60 K(+1.0%) | $558.20 K(+8.0%) |
| Dec 2023 | $516.70 K(+424.0%) | $140.20 K(+1.0%) | $516.80 K(+27.3%) |
| Sep 2023 | - | $138.80 K(+0.9%) | $406.10 K(+39.0%) |
| Jun 2023 | - | $137.60 K(+37.3%) | $292.10 K(+64.8%) |
| Mar 2023 | - | $100.20 K(+239.7%) | $177.20 K(+79.7%) |
| Dec 2022 | $98.60 K | $29.50 K(+19.0%) | $98.60 K(+0.5%) |
| Sep 2022 | - | $24.80 K(+9.3%) | $98.10 K(+21.4%) |
| Jun 2022 | - | $22.70 K(+5.1%) | $80.80 K(+28.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $21.60 K(-25.5%) | $62.80 K(+47.8%) |
| Dec 2021 | $42.50 K(>+9900.0%) | $29.00 K(+286.7%) | $42.50 K(+214.8%) |
| Sep 2021 | - | $7500.00(+59.6%) | $13.50 K(+125.0%) |
| Jun 2021 | - | $4700.00(+261.5%) | $6000.00(+361.5%) |
| Mar 2021 | - | $1300.00(>+9900.0%) | $1300.00(>+9900.0%) |
| Dec 2020 | $0.00 | - | - |
| Dec 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
FAQ
- What is TransCode Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for TransCode Therapeutics?
- What is TransCode Therapeutics annual D&A year-on-year change?
- What is TransCode Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly D&A year-on-year change?
- What is TransCode Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for TransCode Therapeutics?
- What is TransCode Therapeutics TTM D&A year-on-year change?
What is TransCode Therapeutics annual depreciation & amortization?
The current annual D&A of RNAZ is $516.70 K
What is the all time high annual D&A for TransCode Therapeutics?
TransCode Therapeutics all-time high annual depreciation & amortization is $516.70 K
What is TransCode Therapeutics annual D&A year-on-year change?
Over the past year, RNAZ annual depreciation & amortization has changed by +$418.10 K (+424.04%)
What is TransCode Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of RNAZ is $127.50 K
What is the all time high quarterly D&A for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly depreciation & amortization is $142.80 K
What is TransCode Therapeutics quarterly D&A year-on-year change?
Over the past year, RNAZ quarterly depreciation & amortization has changed by -$11.30 K (-8.14%)
What is TransCode Therapeutics TTM depreciation & amortization?
The current TTM D&A of RNAZ is $552.10 K
What is the all time high TTM D&A for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM depreciation & amortization is $563.40 K
What is TransCode Therapeutics TTM D&A year-on-year change?
Over the past year, RNAZ TTM depreciation & amortization has changed by +$146.00 K (+35.95%)